We are where machine learning meets cancer biology

Accelerating Therapeutic Discovery

Resonant's platform allows for the simultaneous discovery of novel targets and high affinity, functional antibodies with unprecedented speed. We use a combination of unique biological insights, high throughput screening, and big data understanding to rapidly discover and prioritize therapeutic candidates.

Each cycle, we have discovered unappreciated therapeutic targets which are uniquely functional in the tumor microenvironment.

12

months per cycle

2000

antibody candidates per cycle

any

solid tumor

Biology First

Resonant begins with a biology-forward approach, letting the tumor microenvironment drive target and candidate selection instead of attempting to pick from often-biased experimental studies. Specific tumor microenvironment factors are critical to the malignant cell state, but are not present in traditional discovery models.

Researchers agree that targeting the microenvironment state is critical to combating cancer, but until now could not develop effective therapies.

Most cancer research uses either culture systems lacking microenvironment factors, or heterogeneous tumors which mask critical signals and are not amenable to high-throughput discovery. Our unique platform recapitulates the tumor microenvironment. We have already generated therapeutic antibodies which simply have not and would not have been discovered by other methods.

Rich Functional Data

Resonant has created a system of high-dimensional assays to rapidly identify and characterize the antibodies generated for functional activity.

Additional screens are used to specifically identify and rank candidates for antibody drug conjugate (ADC) development. The Resonant process allows identification of novel ADC targets and bypasses the use of costly and time consuming individual candidate development programs.

Intelligently Driven

Resonant combines biology with machine learning technologies to assess and prioritize our large libraries of candidates. Our proprietary Rapid Prioritization Engine integrates novel functional target annotation with publicly available data to assign a value score to every therapeutic candidate generated.

We move from model to therapeutic candidate at unprecedented speeds.

Traditional Pharmaceutical Discovery

5+ years

Resonant Therapeutics

1 year

A Partner in Therapeutic Development

Resonant specializes in rapidly creating a library of candidate and target insights which partners can subsequently develop in a standard pharmaceutical pipeline. Our pipeline and model can be modified according to partner insights to better replicate a key disease state.